Astellas Pharma Inc - Company Profile
All the data and insights you need on Astellas Pharma Inc in one report.
- Save hours of research time and resources with
our up-to-date Astellas Pharma Inc Strategy Report
- Understand Astellas Pharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Astellas Pharma Inc (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, cancer, nephrology, infectious diseases, and metabolic diseases, immunodeficiency, and transplantation. The company strives to develop new drugs to address high unmet medical needs with focus on biology and modality. Its pipeline consists of drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Chuo-Ku, Tokyo, Japan.
Determine Astellas Pharma Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.
Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Astellas Pharma Inc’s relevant decision makers and contact details.
Proactively evaluate Astellas Pharma Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
Identify which of Astellas Pharma Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
Understand Astellas Pharma Inc’s commercialized product portfolio to stay one step ahead of the market.
Understand the current and future drug revenue for Astellas Pharma Inc and assess market opportunity for new entrants with patient population 8-year forecasts.
Track drug and patent expiries along with geographies impacted.
Improve competitive bidding with insights into all publicly disclosed IT services contracts for Astellas Pharma Inc (including IT outsourcing, business process outsourcing, systems integration & consulting and more).
IT Client Prospector provides intelligence on Astellas Pharma Inc’s likely spend across technology areas enabling you to understand the digital strategy.
Products and Services
|Xtandi- Treatment of Prostate Cancer
|Xospata- Acute Myeloid Leukemia
|Padcev- Metastatic Urothelial Cancer
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
|In February, the company launched a new monotherapy to treat patients with relapsed or refractory acute myeloid leukemia with an FLT3 mutation (FLT3mut+)1.
|In February, the company received approval from Japan's Ministry of Health, Labour and Welfare for the company's supplemental new drug application for PADCEV with KEYTRUDA as a combination therapy for the first-line treatment of adult patients with metastatic urothelial cancer.
|In January, the company and Mass General Brigham announced a collaboration to improve translational medicine and accelerate the early development of novel therapies.
|Astellas Pharma Inc
|Daiichi Sankyo Co Ltd
|Eisai Co Ltd
|Kyowa Kirin Co Ltd
|Taisho Pharmaceutical Holdings Co Ltd
|No. of Employees
Key Financial Charts
|Chief Executive Officer; Director; President
|Chief Financial Officer
|Chief Strategy Officer
|Chief Ethics and Compliance Officer; Chief People Officer; Executive Vice President
|Non Dignissim Eros
|Non Dignissim Eros
|Non Dignissim Eros
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward